Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA), for its Biocon Generics Inc facility, located in Cranbury, New Jersey, U.S.
This is based on a cGMP inspection conducted by the agency between the October 6 to October 10, 2025.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
